Gerresheimer Reports Solid Financial Year 2024 Results Amidst Challenges

Gerresheimer AG has announced stable financial results for 2024, achieving a revenue of EUR 2,035.9 million, up from EUR 1,990.5 million in 2023. The adjusted EBITDA grew to EUR 419.4 million, marking a 4.1% increase. The company's focus on medical devices helped offset destocking effects in its vial business, leading to an improved adjusted EBITDA margin of 20.6%.

Bormioli Pharma's integration is progressing well, and it is expected to boost future revenues starting from 2025. The acquisition is set to enhance Gerresheimer's product offerings, particularly in plastic solutions for biologics. The Group forecasts a 3-5% growth in organic revenue for 2025 and aims to achieve a 22% adjusted EBITDA margin.

The Primary Packaging Glass Division faced challenges due to destocking but showed signs of recovery by the end of 2024. Despite these hurdles, Gerresheimer remains optimistic about continued profitable growth driven by their strategic expansion plans.